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Abstract 
Pre-synaptic secretion of brain-derived neurotrophic factor (BDNF) from noradrenergic 
neurons may protect the Alzheimer’s disease (AD) brain from amyloid pathology. 
While the BDNF polymorphism (rs6265) is associated with faster cognitive decline and 
increased hippocampal atrophy, a replicable genetic association of BDNF with AD risk 
has yet to be demonstrated. This could be due to masking by underlying epistatic 
interactions between BDNF and other loci that encode proteins involved in moderating 
BDNF secretion (DBH and Sortilin). We performed a multi-cohort case-control 
association study of the BDNF, DBH and SORT1 loci comprising 5,682 controls and 
2,454 AD patients from Northern Europe (87% of samples) and Spain (13%). The 
BDNF locus was associated with increased AD risk (odds ratios; OR=1.1-1.2, p=0.005-
0.3), an effect size that was consistent in the Northern European (OR=1.1-1.2, p=0.002-
0.8) but not the smaller Spanish (OR=0.8-1.6, p=0.4-1.0) subset. A synergistic 
interaction between BDNF and sex (synergy factor; SF=1.3-1.5 p=0.002-0.02) 
translated to a greater risk of AD associated with BDNF in women (OR=1.2-1.3, 
p=0.007-0.00008) than men (OR=0.9-1.0, p=0.3-0.6). While the DBH polymorphism 
(rs1611115) was also associated with increased AD risk (OR=1.1, p=0.04) the 
synergistic interaction (SF=2.2, p=0.007) between BDNF (rs6265) and DBH 
(rs1611115) contributed greater AD risk than either gene alone, an effect that was 
greater in women (SF=2.4, p=0.04) than men (SF=2.0, p=0.2). These data support a 
complex genetic interaction at loci encoding proteins implicated in the DBH-BDNF 
inflammatory pathway that modifies AD risk, particularly in women.  
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Introduction  
Understanding the genetic factors that modify risk and/or progression of Alzheimer’s 
disease (AD) is fundamental for the identification and monitoring of at-risk individuals 
and could lead to novel therapeutic targets and biomarkers. Brain-derived neurotrophic 
factor (BDNF) is the most abundant neurotrophin in the brain and is a well-
characterised protective factor against AD pathology. Specifically, it has been reported 
that pre-synaptic secretion of BDNF from noradrenergic neurons modulates neural 
circuitry, synaptic plasticity, neuronal survival and differentiation and protects neurons 
from various types of insult (reviewed in [1]). In accordance with these findings, 
reduced levels of BDNF (mRNA and protein) have been observed in peripheral blood of 
AD patients [2] and in cortical and subcortical brain regions of individuals with AD at 
autopsy [3, 4]. In the aged population and in subjects with mild cognitive impairment 
and AD patients, reduced brain BDNF levels correlate with lower cognitive scores and 
faster cognitive decline [5-7]. Moreover, there is some evidence that genetic variation at 
the BDNF locus may moderate downstream effects of the pathological protein, β-
amyloid, in autosomal dominant AD. For example, asymptomatic adults with signs of 
brain amyloidosis who carry the methionine allele at rs6265 show faster decline in 
episodic memory, lower hippocampal volume and increased tau markers in 
cerebrospinal fluid compared to valine homozygotes [8-12]. This could be attributed to 
the association of this allele with altered intracellular trafficking and reduced secretion 
of BDNF [13-15]. Additionally, there is evidence that the protective effect of lifetime 
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exposure to cognitively stimulating activities on cognitive performance may be weaker 
in carriers of the methionine allele [16]. Thus, the methionine allele may be a prognostic 
biomarker for predicting cognitive decline due to AD. That being said, extensive study 
in over 30 populations (Caucasian, Asian, African and mixed) has failed to demonstrate 
a replicable association of BDNF genetic variants with altered AD risk 
(www.Alzgene.org [17]). 
Studies using rodent models have shown that a reduction in BDNF levels may precede 
the appearance of amyloid plaque pathology [18]. Reduced BDNF levels have been 
associated with altered synaptic plasticity [19-21], increased cortical amyloid plaque 
numbers, and reduced noradrenergic innervation of the hippocampus, frontal cortex, and 
cerebellum [22] of animal models, effects that can be reversed with BDNF treatment 
[23-27].  
Taken together, data from animal and human studies strongly support an important 
neuroprotective effect of BDNF and that an imbalance in BDNF signalling may be an 
early event in AD pathogenesis. It follows that modulation of BDNF secretion could be 
critical to this process. In this regard, previous studies using rodent models have 
reported a feed forward loop between BDNF and the noradrenergic system, whereby 
noradrenaline (norepinephrine) induces astrocytic and neuronal BDNF secretion, which 
in turn stimulates noradrenergic signalling as part of an anti-inflammatory mechanism 
[28-32]. In support of this, reduced noradrenaline levels have also been reported in aged 
and AD brains and it has been hypothesised that increasing noradrenergic signalling in 
the brain could halt the progression of neurodegeneration and cognitive decline 
(reviewed in [33]). Noradrenaline is synthesised from dopamine, a reaction catalysed by 
dopamine beta-hydroxylase (DBH) and is an anti-inflammatory agent that can attenuate 
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the cortical inflammatory response to the Aβ42 peptide [34]. Thus deregulation of DBH-
mediated synthesis of noradrenaline could have downstream effects on BDNF secretion. 
An additional factor in BDNF secretion is the intracellular sorting of BDNF to the 
secretory pathway, which is regulated by binding of the BDNF pro-domain to the 
luminal domain of Sortilin [35]. This interaction prevents BDNF degradation, targets 
BDNF to the secretory pathway [36] and facilitates the release of mature BDNF [37].  
The aims of this first study of Stage 2 of the Epistasis Project (the results of Stage 1 [38-
44] are summarised in Table 1), were to further evaluate the contribution of genetic 
variation at the BDNF locus to AD risk in a large case-control dataset (n=8,136) and 
determine whether the association could be masked by genetic epistasis between BDNF 
variants and sex, age, APOE ε4 status and variants at loci encoding proteins that control 
BDNF secretion (DBH and Sortilin).  
Materials and Methods 
Study population 
DNA samples were collected from individuals of Caucasian European descent by seven 
research centres within two geographical regions namely, Northern Europe (Bristol, 
Nottingham, OPTIMA and Rotterdam) and Spain (Madrid, Oviedo and Santander). All 
AD cases were diagnosed “definite” or “probable” by CERAD or NINCDS-ADRDA 
criteria. AD cases were sporadic, i.e. possible autosomal dominant cases were excluded, 
based on family history. The cohorts in Stage 1 of the Epistasis Project were described 
in [38]. In this Stage 2, the Bonn cohort was replaced by that from Madrid, giving a 
better overall balance between Northern Europe and Spain. The Madrid cohort fulfilled 
our criteria of an all-Caucasian population drawn from a narrow geographical region. 
The demographics of each sample collection are shown in Table 2. Research ethics 
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approval was obtained by each of the participating groups. Written informed consent 
was given for donation of blood samples from all participants, or their legal 
representatives.  
Polymorphism selection 
We downloaded Caucasian European (CEU) population data from the HaploView 
platform (release 27) using gene coordinates (gene +/- 10kbp flanking regions) 
extracted from the UCSC MySQL server (hg18) at https://genome.ucsc.edu/. 
Polymorphisms with a genotype rate <50%, and that were in Hardy-Weinberg 
equilibrium (p<0.001) and with a minor allele frequency (MAF) <5% were removed. 
The remaining polymorphisms were introduced into the tagger function in HaploView. 
A tagging threshold of r2>0.8 and log odds (LOD) score>3.0 was used. The 
“Aggressive Tagging” approach was implemented, which allows a haplotype of up to 
three polymorphisms to be used as a proxy. We identified 34 polymorphisms (5 in 
BDNF, 23 in DBH and 6 in SORT1) that have a minor allele frequency >5% in 
Caucasian Europeans and that cover 80% of the variation  in these genes (Table 3). Due 
to the considerable variation in DBH, coverage of this gene was restricted to rs1611115, 
which has previously been associated with increased AD risk in men aged <75 [39] and 
is responsible for 30-50% of the considerable variation in DBH activity [46-53]. The 12 
polymorphisms were taken forward for genotyping.  
Genotyping and imputation 
Genotyping for all centres except Rotterdam (below) was performed by LGC 
(Hoddesdon, Hertfordshire, UK), using the KASPar technology by KBioscience 
http://www.kbioscience.co.uk. Six to eight duplicate samples and one blank (H2O) 
sample were included on each plate. All blank samples were negative. The concordance 
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between duplicates was 100% with the exception of one discordant sample for BDNF 
rs11030104 in the Bristol dataset, which was removed from analyses. Where data were 
available from previous in-house TaqMan genotyping, LGC genotypes were 100% 
concordant (BDNF rs6265; n=483, DBH rs1611115; n=396). Genotyping in the 
Rotterdam cohort was done on Version 3 Illumina-Infinium-II HumanHap550 SNP 
array (Illumina, San Diego, USA).  Genotypes for the Rotterdam cohort were imputed 
from whole genome data using MACH software (http://www.sph.umich. 
edu/csg/abecasis/MACH/) and with the 1000 genomes project (phase I version 3 
reference panel, positive strand) as a reference. The reliability of imputation was 
estimated for each imputed SNP with the ratio of expected and observed dosage 
variance (O/E ratio). Only samples with high-quality extracted DNA were genotyped. In 
order to allow analysis alongside the genotyped cohorts, the imputed probabilities from 
Rotterdam were converted to genotypes such that a value of 0 was coded as homozygote 
for allele 2, a value of 1 was coded as heterozygote and a value of 2 was coded as 
homozygote for allele 1. It should be noted that a dosage of 1 could be heterozygote, but 
it could also mean that person has a 0.5 probability of being homozygote for allele 1 and 
a 0.5 probability of being homozygote for allele 2. That being said, it is commonplace 
in genetics to round these values to 0/1/2 with the implied corresponding genotypes. 
The supplementary table shows the genotype counts and allele frequencies as well as 
genotyping rate for all individual centres. The genotyping rate for each polymorphism 
ranged from 0.99 to 1.00 in the total dataset. All genotypes were confirmed to be in 
Hardy-Weinberg equilibrium (α=0.001) in controls from all individual centres. APOE 
ε4 genotypes were determined according to the genotypes at rs429358 and rs7412. Tests 
for pair-wise intragenic linkage disequlibrium for the 5 BDNF polymorphisms and the 6 
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SORT1 polymorphisms were consistent with the Haploview data (r<0.8) with the 
exception of rs6265 and rs11030104 in BDNF (r2=0.9) and rs2228604 and rs10745354 
in SORT1 (r2=1.0). The high degree of co-inheritance of these pairs was replicated in 
both the Northern European and Spanish controls. The polymorphisms rs11030104 
(BDNF) and rs10745354 (SORT1) were therefore removed from the study as they 
provided no further information. 
Statistical analyses 
All analyses were performed in R version 3.5.0 [54]. The relative risk (odds ratios and 
95% confidence intervals; CI) for AD was calculated for each of the 10 polymorphisms 
brought forward for analysis using a general linear model for dominant and recessive 
inheritance models controlling for age-at-extraction, sex, APOE ε4 allele and individual 
centre. The Akaike Information Criterion (AIC) was used to compare goodness-of-fit, 
with smaller values of AIC corresponding to preferable models. The statistical power 
for each sample included in the study to detect a significant (α=0.05) association of a 
polymorphism with a minor allele frequency 0.2 (mean of polymorphisms included in 
the study) with AD risk (OR=1.2) under a dominant model and assuming a prevalence 
of AD of 10% in the population aged over 65 is as follows: Total dataset 97%, Northern 
Europe 92% (Bristol 14%, Nottingham 14%, OPTIMA 17%, Rotterdam 78%), Spain 
31% (Madrid 18%, Oviedo 11%, Santander 13%). All tests were first performed in the 
total dataset and subsequently stratifying by geographical region:  Northern 
Europe=Bristol, Nottingham, OPTIMA and Rotterdam; Spain=Madrid, Oviedo and 
Santander. When an association (p<0.05) was observed in the Northern European 
dataset, analyses were subsequently tested in the Rotterdam subset as the only collection 
centre with sufficient statistical power to detect an association. Interactions were 
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assessed using the Synergy Factor (SF) described in [55]. Using this method, the 
SF=actual OR (joint effect of two factors) / predicted OR (product of the OR for each 
factor alone). The null hypothesis states that the actual OR is equal to the predicted OR. 
This method assesses interactions on a multiplicative scale rather than an additive scale. 
Throughout the study, significance was considered at the α=0.05 level. However, due to 
the large number of tests performed (n=224 in total), the Bonferroni cut-off (α=0.0002) 
can be considered as a more stringent cut-off for significance that minimizes the false-
positive associations reported. Associations that surpass this cut-off are indicated in the 
text and figures. 
Results 
Genetic variation at the BDNF locus is associated with increased AD risk 
We tested for association of the 4 BDNF polymorphisms with altered AD risk in the 
total population. The model preferred (lowest AIC) for BDNF1 was the recessive 
inheritance model, whereas the preferred models for BDNF2-4 were the dominant 
models. The OR and 95% CI for the preferred models of each polymorphism are plotted 
in Fig1. The BDNF1 polymorphism, previously shown to regulate BDNF trafficking, 
was not associated (at the α=0.05 level) with altered AD risk in the total (rs6265 MM; 
OR=1.2, p=0.3), Northern European (OR=1.0, p=0.8) or Spanish (OR=1.6, p=0.1) 
datasets (Fig1A). However, the OR in the total dataset was of a similar yet greater 
magnitude to those for BDNF2 (Fig1B; rs12288512 A allele OR=1.1, p=0.04) and 
BDNF3 (Fig1C; (rs113030102 G allele OR=1.1, p=0.005), associations which 
surpassed our cut-off for significance. Both BDNF2 (OR=1.2, p=0.01) and BDNF3 
(OR=1.2, p=0.005) were associated with increased AD risk in the Northern European 
but not Spanish (OR<1.0, p>0.3) populations. The associations of BDNF2-4 were even 
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stronger in the Rotterdam subset (BDNF2; OR=1.2, p=0.002, BDNF3; OR=1.3, 
p=0.0008). Another polymorphism, BDNF4 (Fig1D), that was not significant in the 
total dataset (p=0.08) despite a similar OR (rs11030119 A+; OR=1.1), was associated 
with increased AD risk in the Northern European (OR=1.2, p=0.01) and Rotterdam 
(OR=1.2, p=0.002) but not Spanish (OR=0.8, p=0.2) population. It should be noted that 
none of these associations surpassed the Bonferroni cut-off (p<0.0002) for this study 
(best p=0.0008 for BDNF3 in the Rotterdam dataset).  
To determine whether interactions between BDNF polymorphisms could explain the 
contradictory findings for rs6265 (BDNF1) across multiple populations, we sequentially 
added pair-wise interactions between the 4 BDNF polymorphisms into the model. No 
interaction between BDNF polymorphisms was associated with altered AD risk (p>0.5).  
Women showed increased susceptibility to AD risk-modifying polymorphisms at 
the BDNF locus 
We next tested whether interactions between BDNF polymorphisms and age-at-
sampling, sex and possession of the APOE ε4 allele could contribute to AD risk. We 
found no association of the BDNF1*sex interaction with AD risk (SF=0.95, p=0.9). 
However, inclusion of BDNF2*sex, BDNF3*sex or BDNF4*sex interactions improved 
the AIC for the model and the synergy factors (SF) for these interactions are plotted in 
Fig2A-C. We observed a positive synergistic interaction between BDNF2, BDNF3 and 
BDNF4 and sex in the total dataset; sex*BDNF2 (SF=1.5, p=0.002), sex*BDNF3 
(SF=1.4, p=0.002) and sex*BDNF4 (SF=1.3, p=0.02). The interactions were observed 
in the Northern European dataset (SF=1.4, p=0.02; SF=1.4, p=0.007; SF=1.3, p=0.02, 
respectively) and Rotterdam (SF=1.4, p=0.02, SF=1.5; p=0.01, SF=1.4, p=0.04, 
respectively) datasets and the sex*BDNF2 interaction was also observed in the Spanish 
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population (SF=1.94, p=0.03). To explore these interactions further, BDNF2-4 were 
tested for association with AD in women and men separately in the datasets that showed 
a synergistic interaction (Fig2D-F). While BDNF2 was associated with reduced AD risk 
in Spanish men (OR=0.6, p=0.03), all three polymorphisms were associated with 
increased risk in women from the total (BDNF2; OR=1.3, p=0.0006, BDNF3; OR=1.3, 
p=0.00008, BDNF4; OR=1.2, p=0.007, respectively) and Northern European (OR=1.3, 
p=0.0007, OR=1.4, p=0.00005, OR=1.2, p=0.001, respectively) and Rotterdam 
(OR=1.4, p=0.0001, OR=1.4, p=0.00003, OR=1.4, p=0.0002, respectively) datasets, 
associations that surpassed the Bonferroni cut-off for this study (p<0.0002) in at least 
one of the datasets.  
We next tested for association of interactions between BDNF variants and the APOE ε4 
allele. The BDNF3*ε4 interaction (SF=0.47, p=0.02) was associated with altered AD 
risk in the Spanish dataset and BDNF3 was nominally associated with decreased AD 
risk in Spanish ε4 carriers (OR=0.58, p=0.05) but not in non-carriers (OR=1.2, p=0.2).  
That being said, these interactions may be of less importance since including them in 
the models did not improve the AIC. Interactions between other BDNF variants and ε4 
were not associated with AD risk (p>0.06) and neither were interactions between any 
BDNF variant and age (p>0.2).  
BDNF and DBH polymorphisms act synergistically to increase AD risk in 
Northern European women  
We have previously identified an association of the DBH polymorphism, rs1611115, 
with increased AD risk in men aged <75 [39] in a sample set that overlaps with that 
included in this study. Therefore, unsurprisingly, when testing for an association of 
DBH with AD risk in the total population, we found that the DBH polymorphism was 
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associated with increased risk of AD in the total dataset (rs1611115T+ OR=1.12, 
p=0.04), albeit that the association was not apparent in either of the regional subsets 
(OR=1.1, p=0.1 and OR=1.3, p=0.1). Addition of interactions between the DBH 
polymorphism and age-at-sampling, sex and possession of the APOE ε4 allele did not 
improve the AIC for the model. Since DBH and BDNF have both been implicated in 
regulating noradrenergic neurotransmission, we sought to determine whether 
polymorphisms at the BDNF and DBH loci could interact to alter AD risk. The addition 
of interactions between DBH and all 4 BDNF polymorphisms improved the AIC for the 
model. The SF for the interactions are plotted in Fig3A-D. A synergistic BDNF1*DBH 
interaction contributed to AD risk in the total (SF=2.2, p=0.007) and Northern 
European (SF=2.2, p=0.02) and Rotterdam (SF=2.2, p=0.03) datasets. While the SF 
(SF=1.4) was comparable in the Spanish population (p=0.3), the interaction did not 
reach our cut-off for significance. Since the BDNF polymorphisms have different 
effects in men and women, we next tested the BDNF*DBH interactions in male and 
female subgroups separately. Due to testing rs6265 under a recessive inheritance model, 
the low number of male MM (rs6265), T+ (rs1611115; dominant model) carriers in the 
Spanish dataset (n=7), meant that the BDNF*DBH1 interaction could only be tested in 
the Northern European dataset. In that dataset, the BDNF*DBH1 interaction contributed 
more to AD risk in women (SF=2.4, p=0.04) than men (SF=2.0, p=0.2). The remaining 
BDNF*DBH interactions did not contribute to the AD risk (p>0.1) and it should be 
noted that none of the BDNF1*DBH interactions surpassed the Bonferroni cut-off 
(p<0.0002) for this study.  
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SORT1 genetic variation is not associated with AD risk 
Finally we tested for an association of SORT1 polymorphisms with AD risk. We found 
no association in the total, Northern European or Spanish populations (p>0.05). We 
tested for an association of interactions between the SORT1 polymorphisms and age-at-
sampling, sex and possession of the APOE ε4 allele with AD risk. We observed an 
antagonistic interaction between SORT1e (rs1149175 GG) and sex in the Spanish 
dataset (SORT1e OR=2.2, sex OR=2.1, SF=0.4, p=0.007) and SORT1e was associated 
with increased AD risk in Spanish men (OR=2.27, p=0.002). That being said, these 
interactions may be of less importance since including them in the models did not 
improve the AIC. None of the interactions with the BDNF variants contributed to AD 
risk in the total or regional subsets (p>0.05).  
Discussion 
This multi-cohort study of 5,682 controls and 2,454 AD patients (recruited from seven 
research centres from Northern Europe and Spain) represents a comprehensive 
exploration of the contribution of epistatic interactions between genes encoding proteins 
implicated in BDNF secretion and noradrenergic innervation to AD risk. The main 
finding of this study is the synergistic interaction between BDNF risk-modifying 
variants (BDNF2-4) and sex (SF=1.3 to 1.5) such that the BDNF-associated risk was 
observed in women (OR=1.2 to 1.3) but not men (OR=0.9 to 1.0). We also show 
evidence of a synergistic interaction between the BDNF and DBH loci such that carriers 
of the minor allele at DBH (rs1611115) who are also homozygous for the minor allele at 
BDNF1 (rs6265) are at increased risk of AD (SF=2.2) than carriers of either allele alone 
(BDNF OR=1.1 to 1.2, DBH OR=1.1), an effect that was greater in women (SF=2.4) 
than in men (SF=2.0).  
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In support of the meta-analyses performed by Alzgene, we report only a nominal 
association of rs6265 (BDNF1) with AD risk (OR=1.2, p=0.3). On the other hand, we 
report three novel risk-modifying BDNF polymorphisms that were associated with 
increased AD risk in the total or Northern European populations (OR=1.1, p<0.01). It 
should be noted that the OR for rs6265 was similar to that reported for the associations 
reported for the other 3 polymorphisms. We therefore cannot rule out the possibility that 
rs6265 has a similar frequency to the other BDNF variants in AD patients, but that the 
significance of this increased frequency is attenuated by other covariates in the model, 
namely age-at-collection, sex, APOE ε4 or collection centre Nevertheless, since none of 
these associations were significant when accounting for multiple testing (lowest 
p=0.0008, Bonferroni cut-off = 0.0002), these findings warrant replication in large 
independent cohorts.  
The strongest finding of this study is the interaction between BDNF variants 2-4  
(rs12288512, rs113030102, rs11030119) and sex (SF=1.3 to 1.5) such that women 
carriers from Northern Europe were at greater risk of AD (OR=1.3 to 1.4) than men 
(OR=0.9 to 1.0), associations that were significant even after accounting for multiple 
testing in at least one dataset. The evidence for the BDNF2*sex interaction reported 
here is particularly strong, as it was observed in both the Northern European (increased 
risk in women) and Spanish (decreased in men) subsets as well as the total dataset. This 
is not the first study to identify sex differences related to the BDNF locus in AD, albeit 
that a previous study reported an association of BDNF1 (rs6265) with increased AD risk 
in women from the Han Chinese population [56], a variant that did not interact with sex 
in this study (p=0.9).  Moreover, the gender effect may not be limited to AD; a greater 
neuroprotective effect against methamphetamine-induced toxicity (i.e., greater 
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preservation of corpus striatal dopamine levels) has been reported in male compared to 
female mice over-expressing Bdnf [57]. In another study, modulation of Bdnf 
expression in response to acute stress was impaired in female rats [58]. The mechanism 
underlying the gender difference observed in this and other studies has yet to be fully 
explored. However, a direct interaction between estrogen receptors and BDNF 
transcription has been shown to alter hippocampal physiology during development in 
the rat, suggesting that hormonal variation during a critical time window may contribute 
to sex-specific effects in BDNF transcription [59]. Whether the BDNF variants reported 
here also affect BDNF transcription has yet to be explored. If a functional effect is 
demonstrated, a hypothesis arises whereby BDNF expression may be natively lower in 
adult women, which, when combined with carrying a genetic variant that may also 
affect brain BDNF levels, could have a multiplicative effect on susceptibility to AD 
pathology, thereby increasing risk for AD in female carriers compared to male non-
carriers. This is an intriguing avenue worth pursuing in future functional studies.  
It is possible that BDNF variants could differentially influence a range of brain regions 
and networks. Therefore, functional studies to determine how these variants may 
influence noradrenergic innervation of the hippocampus, frontal cortex, and cerebellum 
could also be informative. Moreover, whether functional effects can be directly 
attributed to the polymorphisms included in the study, or rather to other polymorphisms 
within the linkage disequilibrium blocks that they capture, also warrants further 
investigation.  
We also report a synergistic interaction (SF=2.2) between BDNF1 (rs6265) and DBH1 
(rs1611115) that contributed more to AD risk in Northern European women (SF=2.4) 
than men (SF=2), an association that was not apparent for the other BDNF variants. 
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This result is particularly intriguing since the rs6265 variant alone showed the weakest 
association with AD risk. As the interaction did not survive adjustment for multiple 
testing (p=0.007, Bonferroni cut-off = 0.0002), validation in an independent study is 
necessary. If validated, this interaction could indicate a combinatorial functional effect 
between BDNF and DBH variants that is specific to the rs6265 polymorphism, thus 
highlighting the importance of considering epistatic interactions in genetic studies to 
unmask otherwise hidden associations with AD. We have previously reported a 
synergistic interaction between DBH (rs1611115) and pro-inflammatory cytokines [39, 
45] that contributed to increased risk for AD. As BDNF and DBH are involved in a 
feed-forward anti-inflammatory mechanism, these studies could point toward a complex 
interaction between genes that encode proteins involved in neuroinflammatory 
pathways and furthermore that these interactions may differ according to sex.  
A limitation of this study is the use of Alzheimer’s disease diagnosis as a single end-
point, which does not account for the possibility of disease-modifying effects of these 
variants on brain atrophy or cognitive decline, particularly if these effects are only 
evident at early stages. The ORs reported in this study, although modest (1.1 to 1.6), 
suggest a mild effect on AD risk, as would be expected from a complex genetic disorder 
such as AD.  
Overall, these data suggest a complex interplay between BDNF and sex that warrants 
further investigation in large, independent studies. 
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 (95% CI, p-value) Population 
Study [reference] Interacting genes Genotypes 
All North Europe  North Spain  
Combarros O et al 2009 [38] IL6 x IL10 rs2069837 AA x rs1800871 C+ 1.6 (1.1-2.4, 0.01) 1.7 (1.05-2.6, 0.03) 2.0 (0.9-4.4, 0.09) 
Combarros O et al 2010 [39] DBH x IL1A rs1611115 T+ x rs1800587 TT 1.9 (1.2-3.1, 0.005) 1.7 (1.02-2.8, 0.04) 3.4 (0.9-12.3, 0.07) 
Lehmann DJ et al 2012 [40] HFE x TF rs1799945 CC x rs1130459 AA 1.5 (1.1-2.1, 0.02) 2.0 (1.3-3.05, 0.002) 1.3 (0.7-2.55, 0.4) 
Kölsch H et al 2012 [41] PPARA x INS rs1800206 CC x rs689 TT 1.7 (0.9-3.2, 0.1) 2.5 (1.2-5.4, 0.02) 0.8 (0.2-3.0, 0.7) 
Heun R et al 2012 [42] PPARA x IL1A rs4253766 CC x rs3783550 C+ 1.6 (1.15-2.2, 0.005) 1.7 (1.2-2.5, 0.006) 1.5 (0.7-3.0, 0.3) 
Bullock JM et al 2012 [43] GSTM3 x HHEX/IDE/KIF11 rs7483 A+ x rs1111875 GG 2.3 (1.6-3.2, < 0.00001)a 2.2 (1.5-3.3, 0.0001)a 2.8 (1.2-6.4, 0.015)a 
Medway C et al 2013 [44] CYP19A1 x IL10 rs1062033 GG x rs1800896 A+ 1.9 (1.2-3.25, 0.01)b 1.9 (1.1-3.3, 0.02)b 1.4 (0.35-5.55, 0.65)b 
a
 in ≥ 75 years (the 3-way interaction with age ±75 years gave p = 0.02) 
bin women (the 3-way interaction with gender in North Europe gave p = 0.02) 
 
Table 1. Summary of the results obtained from Stage 1 of the Epistasis Project. Synergy Factors and p-values are given for 
interactions between genes studied in Stage 1. All analyses controlled for age, gender, APOE ε4 and collection centre. Results in bold type 
are significant at p<0.05. 
30  
  
  Age-at-sample-collection (years) Female  APOE ε4+  
  n Mean +/-SD  range n 75+ n % n % 
Controls 5682 82+/-8  60-106 4762 3198 56 1303 23 
  Northern Europe 5239 82+/-7  60-106 4513 2925 56 1231 23 
    Bristol 88 81+/-8  62-96 69 39 44 12 14 
    Nottingham 148 78+/-10 60-104 96 65 44 32 22 
    OPTIMA 208 80+/-7 62-100 154 89 43 49 24 
    Rotterdam 4795 83+/-7  60-106 4194 2732 57 1138 24 
  Spain 443 77+/-10  60-104 249 273 62 72 16 
    Madrid 278 76+/-11  60-104 135 168 60 42 15 
    Oviedo 59 74+/-5  63-87 29 36 61 12 20 
    Santander 106 81+/-8  62-99 85 69 65 18 17 
AD 2454 81+/-8  60-109 1945 1568 64 1218 50 
  Northern Europe 1858 83+/-7  60-101 1589 1196 64 926 50 
    Bristol 210 80+/-9  60-99 160 106 50 137 65 
    Nottingham 253 83+/-8  61-101 211 140 55 151 60 
    OPTIMA 267 79+/-8  61-100 190 123 46 178 67 
    Rotterdam 1128 84+/-6  61-101 1028 827 73 460 41 
  Spain 596 76+/-8  60-109 356 372 62 292 49 
    Madrid 232 75+/-10  60-109 106 147 63 118 51 
    Oviedo 138 77+/-5  63-88 92 86 62 53 38 
    Santander 226 77+/-7  60-98 158 139 62 121 54 
 
Table 2. Demographics of the sample collections used in this study. The number of 
samples (n) in each dataset along with mean age-at-sample collection (+/- standard 
deviation; SD) is given. The sample numbers (n and % of dataset) are also given for the 
demographic variables included in the analyses, i.e., age-at-collection (participants aged 
over 75; n>75 versus <75), sex (female versus male) and APOE ε4 carriers (ε4+ versus 
ε4-).  
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Region Captured Gene Tag SNP 
Kbp Region Coverage Polymorphisms r2 
rs6265(BDNF1) 0.0 intron,ncRNA,missense 4% rs6265 1.0 
rs12288512 (BDNF2) 2.8 near-gene-5 7% rs12288512, rs12273363 0.9-1.0 
rs11030102 (BDNF3) 19.8 intron,near-gene-5 7% rs11030102 , rs10835211 0.9-1.0 
rs11030119 (BDNF4) 67.2 intron, 
untranslated-3 30% 
rs11030119, rs962369, rs7127507, rs1013402, 
rs11030108, rs7124442, rs1519480, rs925946 0.9-10 
rs11030104 (BDNF5) 32.3 intron 15% rs11030104, rs7103411, rs16917237, 
rs10501087 1.0 
rs6265, rs12288512, rs11030104 69.8 intron, 
ncRNA,missense 4% rs6265, rs11030104, rs12288512, rs1491850 0.9-1.0 
rs12288512,rs11030119, rs11030104 5.8 intron 7% rs11030119, rs11030104, rs12288512, 
rs7934165, rs10767665 0.9-1.0 
BDNF;  Coverage 
= 89% 
rs11030102, rs11030119, rs11030104 79.5 intron, 
untranslated-5 15% 
rs11030119, rs11030104, rs11030102 , 




Coverage = 3% rs1611115 (DBH1) 0.0 near-gene-5 3% rs1611115 1.0 





rs4603158, rs2228604, rs3879450, rs7518013, 
rs10745352, rs10858085, rs444387, 
rs3853501, rs3768497, rs11142, rs10745354, 
rs10858086, rs10858092, rs4970752, 
rs4970751, rs1880670, rs443345 
0.9-1.0 
rs17585355(SORT1b) 0.0 intron 4% rs12037569 1.0 
rs7536292(SORT1c) 29.0 intron 7% rs7536292, rs12037569 0.8-1.0 
rs17646665(SORT1d) 0.0 intron 4% rs17585355 1.0 
rs1149175 (SORT1e) 12.4 intron 7% rs1149175, rs11581665 0.9-1.0 
SORT1; Coverage 
= 86% 
rs10745354, rs7536292 (SORT1f) 75.6 intron 4% rs10745354, rs7536292, rs464218 0.9-1.0 
Table 3. Polymorphisms included in the study. The polymorphisms identified as representative of a linkage disequilibrium block 
(TagSNP) are listed for each gene. The size (kbp captured), location (region captured) and coverage of the linkage disequilibrium block 
captured by the TagSNP, known polymorphisms that lie within the LD block (SNPs captured) and the r2 value are listed. The overall 




Figure 1. BDNF main effects on AD risk. The odds ratios (OR) and 95% confidence 
intervals (CI) are plotted for the main effects of the BDNF polymorphisms on AD risk 




Figure 2. BDNF interactions with sex. The synergy factors (SF) and 95% confidence intervals (CI) for the interactions between BDNF 
polymorphisms and sex are plotted (A-C). The odds ratios (OR) and 95% CI for the main effects of BDNF2, BDNF3 and BDNF4 on AD 




Figure 3. BDNF interactions with DBH. The synergy factors (SF) and 95% 
confidence intervals (CI) for the interactions between BDNF1 (A), BDNF2 (B), BDNF3 
(C) and BDNF4 (D) with DBH1 are plotted. The x-axis is plotted on a log-10 scale. P-
values <0.05 are labelled next to the corresponding SF. 
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Supplementary Table. The genotype counts and allele frequencies for each polymorphism included in the study. (A) Genotype (Gtype)  
and (B) allele frequencies are shown for each polymorphism in controls (CTRL) and AD groups for the total dataset (All), Northern Europe 
(N.Eur) and Spain datasets as well as individual centres. 
(A)             
Polymorphism Diagnosis Gtype All Bristol Nottingham OPTIMA Rotterdam N.Eur Madrid Oviedo Santander Spain 
BDNF1 MM 201 2 6 10 164 182 13 3 3 19 
rs6265 MV 1777 26 55 63 1499 1643 90 14 30 134 
 VV 3697 57 87 134 3132 3410 172 42 73 287 
 N 5675 85 148 207 4795 5235 275 59 106 440 
 
CTRL 
Gtype rate 1.00 0.97 1.00 1.00 1.00 1.00 0.99 1.00 1.00 0.99 
 MM 99 10 11 6 42 69 14 6 10 30 
 MV 764 71 85 100 335 591 61 36 76 173 
 VV 1576 129 150 161 751 1191 154 94 137 385 
 N 2439 210 246 267 1128 1851 229 136 223 588 
 
AD 
Gtype rate 0.99 1.00 0.97 1.00 1.00 1.00 0.99 0.99 0.99 0.99 
BDNF2 AA 257 5 5 11 212 233 16 3 5 24 
rs12288512 AG 1756 21 54 58 1495 1628 71 18 39 128 
 GG 3654 54 89 138 3088 3369 187 37 61 285 
 N 5667 80 148 207 4795 5230 274 58 105 437 
 
CTRL 
Gtype rate 1.00 0.91 1.00 1.00 1.00 1.00 0.99 0.98 0.99 0.99 
 AA 106 6 9 16 54 85 13 1 7 21 
 AG 798 58 88 73 401 620 69 50 59 178 
 GG 1535 145 149 176 673 1143 149 83 160 392 
 N 2439 209 246 265 1128 1848 231 134 226 591 
 
AD 
Gtype rate 0.99 1.00 0.97 0.99 1.00 0.99 1.00 0.97 1.00 0.99 
BDNF3 CC 3171 47 75 123 2662 2907 169 36 59 264 
rs11030102 GC 2084 24 64 68 1793 1949 78 19 38 135 
 
CTRL 
GG 399 7 6 16 340 369 17 4 9 30 
36  
 N 5654 78 145 207 4795 5225 264 59 106 429 
 Gtype rate 1.00 0.89 0.98 1.00 1.00 1.00 0.95 1.00 1.00 0.97 
 CC 1314 115 136 145 558 954 136 79 145 360 
 GC 932 80 86 100 470 736 70 56 70 196 
 GG 177 8 22 20 100 150 18 1 8 27 
 N 2423 203 244 265 1128 1840 224 136 223 583 
 
AD 
Gtype rate 0.99 0.97 0.96 0.99 1.00 0.99 0.97 0.99 0.99 0.98 
BDNF4 AA 489 8 13 19 411 451 20 7 11 38 
rs11030119 AG 2282 35 60 80 1935 2110 104 21 47 172 
 GG 2884 39 70 105 2449 2663 145 28 48 221 
 N 5655 82 143 204 4795 5224 269 56 106 431 
 
CTRL 
Gtype rate 1.00 0.93 0.97 0.98 1.00 1.00 0.97 0.95 1.00 0.97 
 AA 219 13 22 24 117 176 23 8 12 43 
 AG 1011 83 103 104 497 787 80 61 83 224 
 GG 1194 108 119 138 514 879 123 64 128 315 
 N 2424 204 244 266 1128 1842 226 133 223 582 
 
AD 
Gtype rate 0.99 0.97 0.96 1.00 1.00 0.99 0.97 0.96 0.99 0.98 
BDNF5 AA 3555 53 83 130 3022 3288 156 40 71 267 
rs11030104 GA 1879 25 58 67 1588 1738 95 16 30 141 
 GG 224 3 6 11 185 205 12 3 4 19 
 N 5658 81 147 208 4795 5231 263 59 105 427 
 
CTRL 
Gtype rate 1.00 0.92 0.99 1.00 1.00 1.00 0.95 1.00 0.99 0.96 
 AA 1502 124 150 153 714 1141 137 90 134 361 
 GA 812 71 88 102 362 623 69 40 80 189 
 GG 119 12 14 9 52 87 15 7 10 32 
 N 2433 207 252 264 1128 1851 221 137 224 582 
 
AD 
Gtype rate 0.99 0.99 1.00 0.99 1.00 1.00 0.95 0.99 0.99 0.98 
DBH CC 3585 55 97 119 3010 3281 194 40 70 304 
rs1611115 TC 1828 28 45 79 1560 1712 70 17 29 116 
 TT 257 3 4 6 225 238 10 2 7 19 
 N 5670 86 146 204 4795 5231 274 59 106 439 
 
CTRL 
Gtype rate 1.00 0.98 0.99 0.98 1.00 1.00 0.99 1.00 1.00 0.99 
37  
 CC 1492 127 156 160 679 1122 149 78 143 370 
 TC 835 67 85 101 391 644 71 52 68 191 
 TT 115 11 11 6 58 86 12 4 13 29 
 N 2442 205 252 267 1128 1852 232 134 224 590 
 
AD 
Gtype rate 1.00 0.98 1.00 1.00 1.00 1.00 1.00 0.97 0.99 0.99 
SORT1 CC 472 6 15 21 399 441 17 6 8 31 
rs10745354 CT 2348 36 50 91 1988 2165 108 25 50 183 
 TT 2846 40 83 93 2408 2624 148 26 48 222 
 N 5666 82 148 205 4795 5230 273 57 106 436 
 
CTRL 
Gtype rate 1.00 0.93 1.00 0.99 1.00 1.00 0.98 0.97 1.00 0.98 
 CC 183 14 17 25 91 147 14 5 17 36 
 CT 972 87 98 102 463 750 80 53 89 222 
 TT 1279 108 128 139 574 949 133 79 118 330 
 N 2434 209 243 266 1128 1846 227 137 224 588 
 
AD 
Gtype rate 0.99 1.00 0.96 1.00 1.00 0.99 0.98 0.99 0.99 0.99 
SORT1 AA 110 2 6 6 89 103 4 0 3 7 
rs1149175 AG 1402 20 20 56 1190 1286 69 19 28 116 
 GG 4160 65 120 142 3516 3843 202 40 75 317 
 N 5672 87 146 204 4795 5232 275 59 106 440 
 
CTRL 
Gtype rate 1.00 0.99 0.99 0.98 1.00 1.00 0.99 1.00 1.00 0.99 
 AA 55 2 4 7 31 44 3 1 7 11 
 AG 562 61 59 63 252 435 47 24 56 127 
 GG 1825 147 182 194 845 1368 182 112 163 457 
 N 2442 210 245 264 1128 1847 232 137 226 595 
 
AD 
Gtype rate 1.00 1.00 0.97 0.99 1.00 0.99 1.00 0.99 1.00 1.00 
SORT1 AA 5047 76 127 182 4259 4644 252 54 97 403 
rs17585355 CA 611 10 18 25 526 579 20 4 8 32 
 CC 15 0 2 1 10 13 1 1 0 2 
 N 5673 86 147 208 4795 5236 273 59 105 437 
 
CTRL 
Gtype rate 1.00 0.98 0.99 1.00 1.00 1.00 0.98 1.00 0.99 0.99 
 AA 2200 191 213 233 1010 1647 216 129 208 553 
 
AD 
CA 228 18 27 32 113 190 13 9 16 38 
38  
 CC 9 0 1 1 5 7 1 0 1 2 
 N 2437 209 241 266 1128 1844 230 138 225 593 
 Gtype rate 0.99 1.00 0.95 1.00 1.00 0.99 0.99 1.00 1.00 0.99 
SORT1 AA 4880 77 131 178 4103 4489 243 51 97 391 
rs17646665a GA 759 11 15 29 654 709 33 8 9 50 
 GG 38 0 0 0 38 38 0 0 0 0 
 N 5677 88 146 207 4795 5236 276 59 106 441 
 
CTRL 
Gtype rate 1.00 1.00 0.99 1.00 1.00 1.00 0.99 1.00 1.00 1.00 
 AA 2162 186 214 243 982 1625 210 127 200 537 
 GA 268 23 34 21 136 214 20 9 25 54 
 GG 14 1 1 1 10 13 1 0 0 1 
 N 2444 210 249 265 1128 1852 231 136 225 592 
 
AD 
Gtype rate 1.00 1.00 0.98 0.99 1.00 1.00 1.00 0.99 1.00 0.99 
SORT1 AA 473 6 15 21 399 441 18 6 8 32 
rs2228604a AC 2344 35 49 91 1987 2162 107 25 50 182 
 CC 2849 40 81 96 2409 2626 148 27 48 223 
 N 5666 81 145 208 4795 5229 273 58 106 437 
 
CTRL 
Gtype rate 1.00 0.92 0.98 1.00 1.00 1.00 0.98 0.98 1.00 0.99 
 AA 182 14 15 25 91 145 15 5 17 37 
 AC 976 88 97 102 462 749 82 54 91 227 
 CC 1275 107 126 140 575 948 132 78 117 327 
 N 2433 209 238 267 1128 1842 229 137 225 591 
 
AD 
Gtype rate 0.99 1.00 0.94 1.00 1.00 0.99 0.99 0.99 1.00 0.99 
SORT1 CC 162 4 5 5 130 144 11 2 5 18 
rs7536292a CT 1606 19 46 56 1353 1474 79 20 33 132 
 TT 3886 61 96 147 3312 3616 165 37 68 270 
 N 5654 84 147 208 4795 5234 255 59 106 420 
 
CTRL 
Gtype rate 1.00 0.95 0.99 1.00 1.00 1.00 0.92 1.00 1.00 0.95 
 CC 81 9 5 12 26 52 13 6 10 29 
 CT 701 64 70 66 319 519 71 42 69 182 
 TT 1646 136 169 186 783 1274 142 83 147 372 
 
AD 
N 2428 209 244 264 1128 1845 226 131 226 583 
39  
 Gtype rate 0.99 1.00 0.96 0.99 1.00 0.99 0.97 0.95 1.00 0.98 
 
(B)                         
Polymorphism Diagnosis Allele All Bristol Nottingham OPTIMA Rotterdam N.Eur Madrid Oviedo Santander Spain 
BDNF1 M 0.19 0.18 0.23 0.20 0.19 0.19 0.21 0.17 0.17 0.20 
rs6265   
  
        
  




V 0.81 0.82 0.77 0.80 0.81 0.81 0.79 0.83 0.83 0.80 
  M 0.20 0.22 0.22 0.21 0.19 0.20 0.19 0.18 0.22 0.20 
    
  
        
  




V 0.80 0.78 0.78 0.79 0.81 0.80 0.81 0.82 0.78 0.80 
BDNF2  A 0.20 0.19 0.22 0.19 0.20 0.20 0.19 0.21 0.23 0.20 
rs12288512   
  
        
  




G 0.80 0.81 0.78 0.81 0.80 0.80 0.81 0.79 0.77 0.80 
  A 0.21 0.17 0.22 0.20 0.23 0.21 0.21 0.19 0.16 0.19 
    
  
        
  




G 0.79 0.83 0.78 0.80 0.77 0.79 0.79 0.81 0.84 0.81 
BDNF3  C 0.75 0.76 0.74 0.76 0.74 0.74 0.79 0.77 0.74 0.77 
rs11030102   
  
        
  




G 0.25 0.24 0.26 0.24 0.26 0.26 0.21 0.23 0.26 0.23 
  C 0.73 0.76 0.73 0.74 0.70 0.72 0.76 0.79 0.81 0.79 
    
  
        
  




G 0.27 0.24 0.27 0.26 0.30 0.28 0.24 0.21 0.19 0.21 
BDNF4  A 0.29 0.31 0.30 0.29 0.29 0.29 0.27 0.31 0.33 0.29 
rs11030119   
  
        
  




G 0.71 0.69 0.70 0.71 0.71 0.71 0.73 0.69 0.67 0.71 
  A 0.30 0.27 0.30 0.29 0.32 0.31 0.28 0.29 0.24 0.27 
    
  
        
  




G 0.70 0.73 0.70 0.71 0.68 0.69 0.72 0.71 0.76 0.73 
BDNF5  A 0.79 0.81 0.76 0.79 0.80 0.79 0.77 0.81 0.82 0.79 
rs11030104   
  
        
  




G 0.21 0.19 0.24 0.21 0.20 0.21 0.23 0.19 0.18 0.21 
40  
  A 0.78 0.77 0.77 0.77 0.79 0.78 0.78 0.80 0.78 0.78 
    
  
        
  




G 0.22 0.23 0.23 0.23 0.21 0.22 0.22 0.20 0.22 0.22 
DBH  C 0.79 0.80 0.82 0.78 0.79 0.79 0.84 0.82 0.80 0.82 
rs1611115   
  
        
  




T 0.21 0.20 0.18 0.22 0.21 0.21 0.16 0.18 0.20 0.18 
  C 0.78 0.78 0.79 0.79 0.78 0.78 0.80 0.78 0.79 0.79 
    
  
        
  




T 0.22 0.22 0.21 0.21 0.22 0.22 0.20 0.22 0.21 0.21 
SORT1  C 0.29 0.29 0.27 0.32 0.29 0.29 0.26 0.32 0.31 0.28 
rs10745354   
  
        
  




T 0.71 0.71 0.73 0.68 0.71 0.71 0.74 0.68 0.69 0.72 
  C 0.27 0.28 0.27 0.29 0.29 0.28 0.24 0.23 0.27 0.25 
    
  
        
  




T 0.73 0.72 0.73 0.71 0.71 0.72 0.76 0.77 0.73 0.75 
SORT1  A 0.14 0.14 0.11 0.17 0.14 0.14 0.14 0.16 0.16 0.15 
rs1149175   
  
        
  




G 0.86 0.86 0.89 0.83 0.86 0.86 0.86 0.84 0.84 0.85 
  A 0.14 0.15 0.14 0.15 0.14 0.14 0.11 0.09 0.15 0.13 
    
  
        
  




G 0.86 0.85 0.86 0.85 0.86 0.86 0.89 0.91 0.85 0.87 
SORT1  A 0.94 0.94 0.93 0.94 0.94 0.94 0.96 0.95 0.96 0.96 
rs17585355   
  
        
  




C 0.06 0.06 0.07 0.06 0.06 0.06 0.04 0.05 0.04 0.04 
  A 0.95 0.96 0.94 0.94 0.95 0.94 0.97 0.97 0.96 0.96 
    
  
        
  




C 0.05 0.04 0.06 0.06 0.05 0.06 0.03 0.03 0.04 0.04 
SORT1 A 0.93 0.94 0.95 0.93 0.92 0.93 0.94 0.93 0.96 0.94 
rs17646665a   
  
        
  




G 0.07 0.06 0.05 0.07 0.08 0.07 0.06 0.07 0.04 0.06 





        
  
      
  
41  
  G 0.06 0.06 0.07 0.04 0.07 0.06 0.05 0.03 0.06 0.05 
SORT1  A 0.29 0.29 0.27 0.32 0.29 0.29 0.26 0.32 0.31 0.28 
rs2228604a   
  
        
  




C 0.71 0.71 0.73 0.68 0.71 0.71 0.74 0.68 0.69 0.72 
  A 0.28 0.28 0.27 0.28 0.29 0.28 0.24 0.23 0.28 0.25 
    
  
        
  




C 0.72 0.72 0.73 0.72 0.71 0.72 0.76 0.77 0.72 0.75 
SORT1  C 0.17 0.16 0.19 0.16 0.17 0.17 0.20 0.20 0.20 0.20 
rs7536292a   
  
        
  




T 0.83 0.84 0.81 0.84 0.83 0.83 0.80 0.80 0.80 0.80 
  C 0.18 0.20 0.16 0.17 0.16 0.17 0.21 0.21 0.20 0.21 
    
  
        
  




T 0.82 0.80 0.84 0.83 0.84 0.83 0.79 0.79 0.80 0.79 
 
 
